http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jehun Kim ),( Changmin Choi ),( Mihyun Kim ),( Sungyong Lee ),( Cheolkyu Park ),( Yoonsoo Chang ),( Kyeyoung Lee ),( Seungjoon Kim ),( Seihoon Yang ),( Jeongseon Ryu ),( Jeongeun Lee ),( Shinyup Lee 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Introduction We aimed to assess the clinical effect of sequential treatment of afatinib and osimertinib with the use of real-world data in South Korea in patients with non-small cell lung cancer harboring EGFR mutations. Materials and Methods Electronic records of EGFR-mutated NSCLC patients who received first line afatinib and second line osimertinib (group A) or other chemotherapies (group B) between October 2014 and December 2019 across 16 hospitals were reviewed. Primary outcome was to measure time on treatment (TOT), and second outcomes was overall survival (OS). Results Of total 749 patients received frontline afatinib treatment, 322 (134 in group A and 188 in group B) without missing values were selected. Overall median TOT was 32.8 months (95% confidence interval [CI]: 27.3-38.2) in group A and 20.5 months (95% CI: 18.9-22.0) in group B. In group A, presence of hepatic metastasis showed shorter overall median TOT (22.0 months versus [vs]. 39.5 months, P <0.001), and presence of bone metastasis also showed shorter TOT (27.6 months vs. 39.5 months, P = 0.019); However, no significant differences were observed in other characteristics, including EGFR mutation profile (Del 19: 31.0 months vs. L858R: 27.2 months, P = 0.822) and presence of brain metastasis (26.4 months vs. 35.2 months, P = 0.106). In the multivariate analysis of overall TOT, liver metastasis (hazard ratio [HR]: 1.93, 95% CI: 1.06-3.53, P = 0.031) and pericardial metastasis (HR: 2.83, 95% CI: 1.01-7.88) showed poor survival outcome in group A. Conclusion In this real-world experience, sequential treatment with afatinib and osimertinib showed better survival outcome than afatinib treatment followed by other therapeutic regimens. These Results are in line with other previous studies implicating that this sequential treatment may provide sustained clinical benefit to NSCLC patients harboring EGFR mutations, and may warrant further investigations.